Diamyd implements fully underwritten rights issue and strengthens negotiation position
The Diamyd Medical Board of Directors has, subject to approval at the shareholder’s meeting, decided to implement a preferential rights issue of 220 MSEK. The new share issue strengthens Diamyd´s negotiation position in the ongoing process to find an industrial partner as well as secures financing of the Phase III studies. The rights issue is 100% underwritten through undertakings by existing shareholders and underwriters.The market for treatment of newly diagnosed young type 1 diabetes patients in Europe and the US is estimated to exceed 1 billion dollars per year. Based on the recent